Physician profile
Nan Chen
NPI 1558749887
$33,547.48
in general payments reported to CMS, 2019-2025
25 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $97.02 · 2022: $6,084 · 2023: $3,960 · 2024: $8,388 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $1,693 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $843 · Travel and Lodging: $558 · Grant: $350 · Long Term Medical Supply Or Device Loan: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,550.10 |
| Food and Beverage | $1,693.26 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $842.70 |
| Travel and Lodging | $558.19 |
| Grant | $350.00 |
| Long Term Medical Supply Or Device Loan | $199.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $6,404.79 | 2024-2025 | Zoladex |
| Astrazeneca Pharmaceuticals Lp | $5,912.14 | 2019-2025 | Enhertu |
| Genentech USA, INC. | $4,686.29 | 2025 | Kadcyla, Herceptin, Perjeta |
| Gilead Sciences, INC. | $3,506.29 | 2022-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $2,679.88 | 2019-2025 | |
| Daiichi Sankyo INC. | $2,668.19 | 2024-2025 | Datroway, Enhertu |
| Ge Healthcare | $2,616.00 | 2022 | |
| Seagen INC. | $2,256.58 | 2023 | Tukysa |
| Stemline Therapeutics INC. | $1,566.33 | 2023-2025 | Orserdu |
| Pfizer INC. | $317.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $248.67 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $145.97 | 2019 | |
| Genzyme Corporation | $120.94 | 2019 | |
| Lilly USA, LLC | $86.67 | 2019-2020 | |
| Amgen INC. | $80.28 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $64.32 | 2019 | |
| Rigel Pharmaceuticals, INC. | $55.97 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $49.47 | 2019 | |
| Agios Pharmaceuticals, INC. | $30.40 | 2019 | |
| Astellas Pharma US INC | $21.69 | 2019 | |
| Incyte Corporation | $15.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.87 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.